SciClone Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:SciClone Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3478
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
SciClone Pharmaceuticals Inc (SciClone), a subsidiary of Silver Biotech Investment Ltd, develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin) is an immunostimulatory agent indicated for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), sepsis, certain cancers, and as an immune system enhancer. SciClone also markets other pharmaceutical products in China including DC Bead, a product for the embolization of malignant hypervascularized tumors. It also has several drug candidates in various clinical development states intended for the treatment of cancer and cardiovascular diseases. The company has presence in Beijing and Shanghai in China; Hong Kong and Vietnam. SciClone is headquartered in Foster City, California, the US.

SciClone Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 10
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 11
Licensing Agreements 12
SciClone Pharma Enters into Licensing Agreement with Soligenix 12
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 13
Phosplatin Therapeutics Enters into Licensing Agreement with SciClone Pharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Medicines Company Enters into Licensing Agreement with SciClone 16
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 17
SciClone Pharma And Zensun (Shanghai) Science & Technology Enter Into Licensing Agreement For Neucardin 18
Equity Offering 19
SciClone Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
Acquisition 21
GL Capital Led Consortium Acquires SciClone Pharma for up to USD605 Million 21
SciClone Pharmaceuticals Inc – Key Competitors 23
SciClone Pharmaceuticals Inc – Key Employees 24
SciClone Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 09, 2017: SciClone Reports Second Quarter 2017 Financial Results 26
May 10, 2017: SciClone Reports First Quarter 2017 Financial Results 28
Mar 06, 2017: SciClone Reports 2016 Financial Results And 2017 Outlook 30
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SciClone Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 10
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 11
SciClone Pharma Enters into Licensing Agreement with Soligenix 12
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 13
Phosplatin Therapeutics Enters into Licensing Agreement with SciClone Pharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Medicines Company Enters into Licensing Agreement with SciClone 16
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 17
SciClone Pharma And Zensun (Shanghai) Science & Technology Enter Into Licensing Agreement For Neucardin 18
SciClone Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
GL Capital Led Consortium Acquires SciClone Pharma for up to USD605 Million 21
SciClone Pharmaceuticals Inc, Key Competitors 23
SciClone Pharmaceuticals Inc, Key Employees 24
SciClone Pharmaceuticals Inc, Subsidiaries 25

List of Figures
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[SciClone Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Electricity & Water Authority:企業の戦略的SWOT分析
    Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Fluidigm Corp (FLDM):企業の財務・戦略的SWOT分析
    Summary Fluidigm Corp (Fluidigm), formerly Mycometrix Corp, develops, manufactures, and markets life science analytical and preparatory systems for mass cytometry, high-throughput genomics, and single-cell genomics markets. The company offers analytical systems and instruments, preparatory instrumen …
  • Toll Brothers, Inc.:企業の戦略・SWOT・財務情報
    Toll Brothers, Inc. - Strategy, SWOT and Corporate Finance Report Summary Toll Brothers, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Rex International Holding Ltd (5WH):企業の財務・戦略的SWOT分析
    Summary Rex International Holding Ltd (Rex International), formerly Rex International Holding Pte Ltd is an independent exploration and production oil company. The company develops oil and gas properties across Singapore. It operates substantial oil and gas exploration concessions in the UAE, Oman, …
  • Vital Images Inc:企業の戦略的SWOT分析
    Vital Images Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Tenaga Nasional Berhad (TENAGA)-エネルギー分野:企業M&A・提携分析
    Summary Tenaga Nasional Berhad (TNB) is an electricity utility that generates, transmits, distributes and supplies power. It develops, operates and maintains a portfolio of power generating units. The company produces electricity from crude oil, natural gas, hydro, coal and gas sources. TNB also sup …
  • Weis Markets, Inc.:戦略・SWOT・企業財務分析
    Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report Summary Weis Markets, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Coca-Cola FEMSA SAB de CV:企業の戦略・SWOT・財務情報
    Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AviAlliance GmbH:企業の戦略・SWOT・財務情報
    AviAlliance GmbH - Strategy, SWOT and Corporate Finance Report Summary AviAlliance GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Active Biotech AB (ACTI)-製薬・医療分野:企業M&A・提携分析
    Summary Active Biotech AB (Active Biotech) is a biotechnology company that undertakes the development and commercialization of pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company has five projects in clinical development of which three have been licensed o …
  • Pharma Mar SA (PHM)-製薬・医療分野:企業M&A・提携分析
    Summary Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced …
  • Shell Canada Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Shell Canada Ltd (Shell Canada) a subsidiary of Royal Dutch Shell plc is an integrated oil and gas company that offers upstream and downstream services. The company's upstream services include markets and trades natural gas and power and exploration and extraction of natural gas. Its downstr …
  • Mitsui E&S Holdings Co., Ltd. (7003):電力:M&Aディール及び事業提携情報
    Summary Mitsui E&S Holdings Co., Ltd. (Mitsui E&S) is a shipbuilding and engineering product manufacturing company. It has diversified business operations comprising environment recycling, construction of social infrastructure, advanced machinery systems, IT-related activities, ships and oceans, pla …
  • Compania Minera Antamina SA:企業の戦略・SWOT・財務情報
    Compania Minera Antamina SA - Strategy, SWOT and Corporate Finance Report Summary Compania Minera Antamina SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • IsoRay Inc (ISR):製薬・医療:M&Aディール及び事業提携情報
    Summary IsoRay Inc (IsoRay), formerly Century Park Pictures Corporation, is a medical technology company which develops, manufactures and markets isotope-based personalized brachytherapy products and devices for the treatment of cancer and other malignant tumors. The company produced Cesium-131, a r …
  • Owens Corning (OC):企業の財務・戦略的SWOT分析
    Owens Corning (OC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • ArQule Inc (ARQL):製薬・医療:M&Aディール及び事業提携情報
    Summary ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including …
  • Gulf Pharmaceutical Industries PSC (JULPHAR):製薬・医療:M&Aディール及び事業提携情報
    Summary Gulf Pharmaceutical Industries PSC (Julphar) is a pharmaceutical company that manufactures and distributes medicines in the Middle East and North Africa (MENA) region. The company's product portfolio consists of antibiotics, antiseptics, wound care and biotechnology, women care, adult primar …
  • Allscripts Healthcare Solutions, Inc.:企業の戦略・SWOT・財務分析
    Allscripts Healthcare Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Allscripts Healthcare Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Respira Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Respira Therapeutics Inc (Respira) is a pharmaceutical development company that develops dry powder inhaler technologies. The company develops Inhaler technologies to enable targeted lung delivery of drugs to treat pulmonary diseases. It develops products used for the treatment of pulmonary …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆